WHO releases new target product profiles for urgently needed antibiotics: Geneva Thursday, March 12, 2026, 09:00 Hrs [IST] The World Health Organization (WHO) published three new ...
New guidance encourages pharmaceutical companies to focus research where need is most urgent, amid a rising AMR threat ...
We need a reliable pipeline with new antibacterial agents that are innovative, affordable, accessible to all those who need ...
Researchers have identified a lipid-driven biophysical mechanism that allows tuberculosis-causing mycobacteria to survive inside human immune cells, a discovery that could inform novel ...
Detailed price information for United Laboratories International Holdings Ltd (ULIHF) from The Globe and Mail including charting and trades.
Can you please introduce yourself and your role at LifeArc? As part of my Biochemistry degree at University of Leeds, I completed an industry placement at LifeArc. This was my first introduction to ...
Phase III results from a clinical trial of a typhoid conjugate vaccine (TCV), EuTYPH-C Inj. Multi-dose, demonstrate that it is safe and immunogenic in typhoid-endemic populations in sub-Saharan Africa ...
Cefiderocol was effective in multiple gram-negative bacterial infections, particularly in patients with complex clinical profiles and prior antibiotic exposure, with no significant difference in ...
Vancomycin is a common antibiotic used to treat gram-positive bacterial infections. It targets a key building block of the bacterial cell wall called Lipid II, but it can’t reach this lipid in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results